Cargando…

The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections

Patients with systemic lupus erythematosus (SLE) suffer frequent infections that account for significant morbidity and mortality. T cell cytotoxic responses are decreased in patients with SLE, yet the responsible molecular events are largely unknown. We find an expanded CD8CD38(high) T cell subset i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katsuyama, Eri, Suarez-Fueyo, Abel, Bradley, Sean J., Mizui, Masayuki, Marin, Ana V., Mulki, Lama, Krishfield, Suzanne, Malavasi, Fabio, Yoon, Joon, Ho Sui, Shannan J., Kyttaris, Vasileios C., Tsokos, George C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577012/ https://www.ncbi.nlm.nih.gov/pubmed/31914379 http://dx.doi.org/10.1016/j.celrep.2019.12.014

Ejemplares similares

Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice
por: Kyttaris, Vasileios C., et al.
Publicado: (2013)

Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling
por: Grammatikos, Alexandros P., et al.
Publicado: (2013)

T Cell Transcriptomes Describe Patient Subtypes in Systemic Lupus Erythematosus
por: Bradley, Sean J., et al.
Publicado: (2015)

Hyaluronic Acid Synthesis Contributes to Tissue Damage in Systemic Lupus Erythematosus
por: Suarez-Fueyo, Abel, et al.
Publicado: (2019)

Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus
por: Morita, Masashi, et al.
Publicado: (2022)

Hypothalamic NAD(+)-Sirtuin Axis: Function and Regulation
por: Roh, Eun, et al.
Publicado: (2020)

Targeting Syk in Autoimmune Rheumatic Diseases
por: Deng, Guo-Min, et al.
Publicado: (2016)

NAD(+), Sirtuins and PARPs: enhancing oocyte developmental competence
por: POLLARD, Charley-Lea, et al.
Publicado: (2022)

Estrogen‐Induced hsa‐miR‐10b‐5p Is Elevated in T Cells From Patients With Systemic Lupus Erythematosus and Down‐Regulates Serine/Arginine‐Rich Splicing Factor 1
por: Ramanujan, Suruchi A., et al.
Publicado: (2021)

EZH2: Its regulation and roles in immune disturbance of SLE
por: Yang, Yiying, et al.
Publicado: (2022)

CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy
por: Chen, Ping-Min, et al.
Publicado: (2022)

Identity of mysterious CD4(+)CD25(-)Foxp3(+ )cells in SLE
por: Horwitz, David A
Publicado: (2010)

Phenotypical changes and clinical significance of CD4(+)/CD8(+) T cells in SLE
por: Yuan, Shiwen, et al.
Publicado: (2022)

Journal Club: Anti‐CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus
por: Boulougoura, Afroditi, et al.
Publicado: (2023)

Sirtuins: Sir2-related NAD-dependent protein deacetylases
por: North, Brian J, et al.
Publicado: (2004)

It takes two to tango: NAD(+) and sirtuins in aging/longevity control
por: Imai, Shin-ichiro, et al.
Publicado: (2016)

Phenotypic Characterization of SLe(x)+ and CLA+ CD4+ T Cells
por: Kuri-Cervantes, Leticia, et al.
Publicado: (2020)

Molecular evolutionary patterns of NAD(+)/Sirtuin aging signaling pathway across taxa
por: Gaur, Uma, et al.
Publicado: (2017)

Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus
por: Mizui, Masayuki, et al.
Publicado: (2018)

Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus
por: Karampetsou, Maria P., et al.
Publicado: (2017)

Rhodium-Complex-Functionalized and Polydopamine-Coated CdSe@CdS Nanorods for Photocatalytic NAD(+) Reduction
por: Boecker, Marcel, et al.
Publicado: (2021)

CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities
por: Ciurtin, Coziana, et al.
Publicado: (2022)

CD38 is methylated in prostate cancer and regulates extracellular NAD(+)
por: Mottahedeh, Jack, et al.
Publicado: (2018)

CD38-NAD(+)-Sirt1 axis in T cell immunotherapy
por: Chatterjee, Shilpak, et al.
Publicado: (2019)

Sirtuin 5 is Dispensable for CD8(+) T Cell Effector and Memory Differentiation
por: Duan, Qianqian, et al.
Publicado: (2021)

Cancer immunosurveillance by CD8 T cells
por: Crispin, José C, et al.
Publicado: (2020)

IL-22 production of effector CD4(+) T-cells is altered in SLE patients
por: Dolff, Sebastian, et al.
Publicado: (2019)

Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
por: Burns, Marie, et al.
Publicado: (2021)

NAD(+) protects against EAE by regulating CD4(+) T-cell differentiation
por: Tullius, Stefan G., et al.
Publicado: (2014)

CD38 regulates ovarian function and fecundity via NAD(+) metabolism
por: Perrone, Rosalba, et al.
Publicado: (2023)

EZH2 as a Regulator of CD8+ T Cell Fate and Function
por: Stairiker, Christopher J., et al.
Publicado: (2020)

The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes
por: Deaglio, Silvia, et al.
Publicado: (2006)

Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases
por: Horwitz, David A., et al.
Publicado: (2021)

The new insight into extracellular NAD(+) degradation‐the contribution of CD38 and CD73 in calcific aortic valve disease
por: Jablonska, Patrycja, et al.
Publicado: (2021)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

ICER is requisite for Th17 differentiation
por: Yoshida, Nobuya, et al.
Publicado: (2016)

The Key Role of NAD(+) in Anti-Tumor Immune Response: An Update
por: Morandi, Fabio, et al.
Publicado: (2021)

Ketosis-prone diabetes and SLE co-presenting in an African lady with previous gestational diabetes
por: Hussain, S, et al.
Publicado: (2017)

Chronic exposure to PM2.5 aggravates SLE manifestations in lupus-prone mice
por: Yariwake, Victor Yuji, et al.
Publicado: (2021)

Flavonoid Apigenin Is an Inhibitor of the NAD(+)ase CD38: Implications for Cellular NAD(+) Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome
por: Escande, Carlos, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c0hkgknn8rsecnhj8senanqpml